Floatz logo

Cixutumumab

Childhood Angiosarcoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Angiosarcoma cohort.

Asset / SponsorPhaseRating
Temsirolimus
National Cancer Institute (NCI)
Phase 2B

Same molecule, other indications

Cixutumumab is also rated in:

Stage IV Breast Cancer AJCC v6 and v7Dormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →